Intensity Therapeutics Inc INTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
-
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
-
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
-
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
-
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Trading Information
- Previous Close Price
- $3.99
- Day Range
- $3.70–3.82
- 52-Week Range
- $3.70–43.50
- Bid/Ask
- $3.70 / $3.85
- Shares Outstanding
- 2.70M
- Market Cap
- $10.19M
- Volume/Avg
- 19,517 / 28,801
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
Valuation
|
Metric
|
INTS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.96 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INTS
|
|---|---|
Quick Ratio | 4.57 |
Current Ratio | 4.86 |
Interest Coverage | — |
Quick Ratio
INTS
Profitability
|
Metric
|
INTS
|
|---|---|
Return on Assets (Normalized) | −100.51% |
Return on Equity (Normalized) | −138.33% |
Return on Invested Capital (Normalized) | −139.82% |
Return on Assets
INTS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Sdzsjsx | Qjvzsl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tjckzgh | Wjvhvr | $67B | |||
| argenx SE ADR
ARGX
| Kxfwwkfr | Kthvf | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ydxvzvtf | Mcvqclx | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Fvpzmwzph | Tnsvhcz | $25B | |||
| BioNTech SE ADR
BNTX
| Xpjxqxss | Jkz | $22B | |||
| Incyte Corp
INCY
| Wrmdsjt | Jvnz | $20B | |||
| Moderna Inc
MRNA
| Wpsydvs | Bmm | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Kjssbkp | Xcng | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Ckkhvxkmm | Qjlk | $13B |
United States